List of Excipients in Branded Drug MIOSTAT

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Alcon Laboratories Inc	MIOSTAT	carbachol	0065-0023	CALCIUM CHLORIDE
Alcon Laboratories Inc	MIOSTAT	carbachol	0065-0023	HYDROCHLORIC ACID
Alcon Laboratories Inc	MIOSTAT	carbachol	0065-0023	MAGNESIUM CHLORIDE
Alcon Laboratories Inc	MIOSTAT	carbachol	0065-0023	POTASSIUM CHLORIDE

MIOSTAT Excipient Strategy and Commercial Opportunities for Carbachol Intraocular Solution

Last updated: September 5, 2026

MIOSTAT is a preservative-free, single-use ophthalmic product containing carbachol 0.01% for rapid intraoperative miosis during cataract and other anterior-segment procedures. Its commercial value is tied less to active-ingredient innovation than to sterile manufacturing, container-closure performance, hospital supply reliability, and delivery convenience.

The strongest product opportunities are a ready-to-use presentation, improved low-volume dosing, reliable U.S. supply, and a differentiated sterile platform that avoids preservative exposure. Excipient changes must preserve isotonicity, pH control, chemical stability, ocular tolerability, and compatibility with intraocular administration.

What is MIOSTAT and how is it used?

MIOSTAT contains carbachol, a direct-acting cholinergic agonist, in a sterile intraocular solution. It is administered by injection into the anterior chamber after cataract extraction and lens implantation to produce miosis and reduce the risk of postoperative pressure elevation associated with retained viscoelastic material [1].

Attribute	MIOSTAT profile
Active ingredient	Carbachol
Strength	0.01%, equivalent to 0.1 mg/mL
Dosage form	Sterile intraocular solution
Route	Intraocular, typically intracameral
Preservative status	Preservative-free, single-dose use
Primary use	Intraoperative miosis
Manufacturer associated with branded product	Alcon Laboratories
FDA regulatory pathway	Approved drug product under an NDA
Commercial setting	Cataract and anterior-segment surgery

The product is used in a highly controlled surgical environment. That limits the value of consumer-facing differentiation but increases the value of low preparation burden, dependable sterility, and compatibility with operating-room workflow.

What excipients are used in MIOSTAT?

MIOSTAT uses a simple aqueous excipient system centered on tonicity and pH control. Public product information identifies mannitol and sodium acetate among the inactive ingredients. The formulation is adjusted to a mildly acidic pH range and is supplied as a sterile, single-use product [1,2].

Excipient function	MIOSTAT approach	Commercial purpose
Tonicity adjustment	Mannitol-based system	Reduces ocular discomfort and tissue stress
Buffering	Sodium acetate system	Controls pH during storage
Vehicle	Sterile water for injection	Provides the aqueous delivery medium
Preservation	No multidose preservative	Avoids intraocular preservative toxicity
pH adjustment	Acid or base adjustment during manufacture	Maintains chemical and ocular tolerability

The exact quantitative composition, pH specification, and manufacturing controls should be taken from the current approved labeling and regulatory file before development decisions are made. Formulation work should treat the existing excipient system as a reference standard rather than assume that a more complex buffer or preservative system would improve the product.

Why is the MIOSTAT excipient strategy commercially important?

The product is administered directly into the eye. Excipients that are acceptable in topical ophthalmic products may be unsuitable for intracameral injection. Benzalkonium chloride, for example, is generally unattractive for an intraocular formulation because of potential toxicity to corneal endothelium and other ocular tissues.

A commercially viable formulation should meet five requirements:

1. Maintain sterility through the full labeled shelf life.
2. Avoid visible particles, precipitation, and pH drift.
3. Preserve isotonicity within an ocularly tolerated range.
4. Minimize chemical degradation of carbachol.
5. Remain compatible with the vial, stopper, syringe, and transfer device.

The simple mannitol-acetate architecture has a regulatory advantage. A generic or follow-on product that retains the reference formulation’s excipient functions may reduce formulation-related questions during development. A novel excipient package creates greater analytical and toxicological burden without necessarily improving clinical performance.

What formulations are protected by MIOSTAT’s product design?

The primary product differentiation is not a complex formulation patent. It is the combination of:

• Very low-dose carbachol in an aqueous sterile vehicle.
• Preservative-free single-dose packaging.
• Intracameral administration.
• Operating-room use after lens implantation.
• Tight control of pH, osmolality, sterility, and particulate matter.

A competing product could use different inactive ingredients if it demonstrates pharmaceutical equivalence or an otherwise acceptable clinical and regulatory profile. The commercial barrier is therefore execution rather than a unique excipient claim.

Potential formulation variants include the following:

Product concept	Excipient strategy	Development value
Reference-like solution	Mannitol and acetate buffer	Lowest formulation-change risk
Lower-buffer formulation	Reduced buffer capacity with tonicity agent	May improve compatibility but requires stability work
Citrate-buffered solution	Citrate in place of acetate	Possible pH control, but new ocular-tolerability and compatibility package
Ready-to-use prefilled syringe	Same or simplified aqueous formulation	Reduces transfer steps and dosing waste
Unit-dose ampoule	Preservative-free aqueous solution	Lower component count, but breakage and extractables must be assessed
Lyophilized carbachol	Mannitol or other bulking agent with reconstitution diluent	Higher complexity and weak commercial rationale unless stability is materially improved

The strongest strategy is usually a reference-like liquid formulation in a presentation designed to reduce preparation errors. A lyophilized version would add reconstitution steps, which conflicts with the main workflow opportunity.

What commercial opportunities exist for MIOSTAT alternatives?

Ready-to-use intracameral presentation

A prefilled syringe or integrated unit-dose delivery system could eliminate vial opening, withdrawal, and transfer into a surgical syringe. The value proposition is strongest if the presentation:

• Delivers the intended volume accurately.
• Minimizes dead volume.
• Prevents needle or syringe substitutions.
• Has validated silicone-oil, tungsten, stopper, and extractables profiles.
• Is compatible with common ophthalmic injection techniques.

The device would require container-closure integrity, sterility assurance, particulate, dose-uniformity, and human-factors testing.

Reliable generic supply

Shortages and procurement instability create an opportunity for a second supplier even where the molecule is old. Hospitals and ambulatory surgery centers generally value consistent availability, predictable packaging, and contract pricing more than incremental pharmacology.

A supplier with domestic or geographically diversified sterile filling capacity could compete through supply reliability. This is particularly relevant for low-volume sterile ophthalmic drugs, where a single manufacturing interruption can affect surgical scheduling.

Low-waste unit-dose packaging

MIOSTAT is used in small quantities. A package containing more volume than routinely needed creates residual waste. A lower-fill-volume presentation could reduce wastage and improve cost per procedure, subject to the need for overfill, withdrawal losses, and administration-device compatibility.

The commercial analysis should measure:

• Nominal fill volume.
• Withdrawable volume.
• Dead volume.
• Number of procedures per package.
• Unused product discarded after opening.
• Packaging cost per administered dose.

Compounding replacement

Compounded intraocular carbachol may be used when an approved product is unavailable, but compounding introduces concerns involving sterility, potency, beyond-use dating, quality systems, and institutional liability. An approved, ready-to-use product can compete by reducing pharmacy preparation and documentation requirements.

This opportunity is strongest in facilities that currently prepare or source compounded intraocular solutions because of supply constraints.

What is the FDA regulatory status of MIOSTAT?

MIOSTAT is an FDA-approved carbachol intraocular product. The regulatory profile is materially different from that of a topical ophthalmic generic because the product is injected into the eye and must meet a higher practical standard for visible and subvisible particulate matter, sterility, container integrity, and tissue compatibility [1].

A follow-on applicant would likely evaluate an abbreviated approval strategy if a suitable reference-listed drug and regulatory pathway are available. The development program would generally need to address:

• Active ingredient identity and strength.
• Sterility and endotoxin controls.
• pH and osmolality.
• Particulate matter.
• Extractables and leachables.
• Container-closure integrity.
• Stability under labeled storage conditions.
• Compatibility with administration components.
• Pharmaceutical equivalence and bioequivalence requirements applicable to the selected pathway.

The formulation should not be changed merely to create novelty. A different buffer or tonicity agent can trigger additional questions about local tolerance and equivalence.

What is the Orange Book and patent status of MIOSTAT?

MIOSTAT is a legacy small-molecule product rather than a recently launched protected therapy. The commercial assessment should distinguish between three forms of protection:

Protection category	Relevance to MIOSTAT
Active-ingredient patent	Carbachol is an established molecule with no apparent modern composition-of-matter barrier
Formulation patent	Any enforceable claims would need to be verified in current patent and regulatory records
Method-of-use patent	Intraoperative miosis is an established clinical use and is unlikely to create a substantial modern exclusivity barrier without specific claim scope
Regulatory exclusivity	Legacy approval status does not indicate a current new-drug exclusivity period
Trademark	MIOSTAT branding may remain relevant even where patent protection does not

The FDA Orange Book should be checked for current patent and exclusivity listings associated with the reference NDA before filing an ANDA or pursuing a 505(b)(2) strategy [3]. A Paragraph IV challenge would have commercial value only if an active, listed patent materially blocked approval or launch. For a legacy carbachol product, the more likely competitive barriers are sterile manufacturing, reference-product identification, supply continuity, and market access.

When does MIOSTAT lose exclusivity?

MIOSTAT’s principal exclusivity risk is unlikely to be a near-term patent cliff. The important question is whether any current listed patent, regulatory exclusivity period, or enforceable formulation claim remains active.

A practical exclusivity timeline is:

Period	Commercial implication
Original launch and early commercialization	Brand established clinical use and surgeon familiarity
Patent and exclusivity expiry	Generic and alternative sterile presentations become more feasible
Mature market	Price, availability, and packaging become the principal competitive factors
Shortage or discontinuation event	Approved substitutes and reliable suppliers gain leverage

Because the product is old, a new entrant should focus on present-day regulatory and manufacturing barriers rather than assume that historical exclusivity controls current market access.

Which companies are challenging or competing with MIOSTAT?

Competition can come from three groups:

Generic carbachol suppliers

These companies compete on approved product availability, contract pricing, and hospital distribution. The main barriers are sterile ophthalmic manufacturing and regulatory equivalence.

Compounding pharmacies

Compounding pharmacies can supply carbachol when commercial products are unavailable. Their advantage is flexibility in fill size and local sourcing. Their disadvantages are variable availability, additional institutional oversight, and a less standardized regulatory position.

Alternative miotic products

Acetylcholine intraocular products and other surgical miotics can compete clinically, although they are not necessarily direct formulation substitutes. The choice depends on surgeon preference, onset and duration of miosis, supply, price, and operating-room protocols.

A new MIOSTAT competitor should position against both approved carbachol products and non-carbacol surgical miotics.

How strong is the MIOSTAT patent estate?

The patent estate appears commercially weak compared with products protected by active composition, formulation, device, and method-of-use patents. MIOSTAT’s strategic defensibility is more likely to arise from:

• Regulatory know-how for sterile intracameral products.
• Validated manufacturing processes.
• Supplier qualification.
• Container-closure performance.
• Hospital purchasing contracts.
• Surgeon familiarity.
• Reliable distribution.

These barriers can support pricing and retention but do not create the same exclusionary power as an active patent portfolio. A new entrant with a compliant, stable, and consistently supplied product could compete without requiring a novel molecule.

What manufacturing and IP barriers affect a new MIOSTAT product?

Manufacturing is the central barrier. Carbachol is used at a low concentration, so small process deviations can affect assay accuracy and dose uniformity. A commercial product must control:

• Low-concentration active blending.
• Bioburden before sterilization or aseptic processing.
• Filter compatibility, if sterile filtration is used.
• Adsorption to process equipment and container surfaces.
• Particulate generation.
• Stopper and seal integrity.
• Fill-volume accuracy.
• Stability under shipping and storage conditions.

A prefilled syringe introduces further issues, including plunger movement, silicone oil, tungsten residues, elastomer compatibility, and extractables. A glass vial has a more familiar regulatory profile but retains preparation steps.

The preferred development path is a simple liquid formulation in a conventional sterile container, followed by a differentiated ready-to-use presentation if the device package can demonstrate meaningful workflow or waste reduction.

How does MIOSTAT compare with alternative surgical miotics?

Factor	MIOSTAT/carbacol	Acetylcholine intraocular products	Compounded miotic products
Primary role	Intraoperative miosis	Intraoperative miosis	May address supply gaps
Formulation opportunity	Preservative-free aqueous solution	Similar sterile constraints	Variable by compounder
Regulatory predictability	Higher for approved product	Depends on product status	Lower and institution-specific
Commercial differentiator	Supply, dose delivery, packaging	Clinical familiarity and availability	Flexibility and local access
Main risk	Sterile manufacturing and supply	Availability and competition	Sterility, potency, and consistency

MIOSTAT’s competitive position depends on dependable delivery rather than broad therapeutic differentiation.

What revenue exposure and market-entry scenarios exist?

MIOSTAT is a procedure-linked product. Revenue depends on cataract surgery volumes, formulary access, distributor contracts, and the number of procedures using an approved miotic.

Three launch scenarios are commercially relevant:

1. A lower-priced vial product enters the market and competes mainly on contracting.
2. A ready-to-use syringe captures a premium by reducing preparation time and waste.
3. A supply-constrained market allows a reliable manufacturer to gain share despite limited formulation differentiation.

A new product should avoid relying solely on price. In sterile ophthalmology, a supply interruption can damage hospital confidence, while consistent availability can support durable purchasing relationships.

Key Takeaways

• MIOSTAT is a preservative-free carbachol 0.01% intraocular solution used for surgical miosis.
• Its excipient strategy is intentionally simple, using tonicity and pH-control components rather than a complex delivery system.
• The strongest formulation strategy is a reference-like aqueous product with improved packaging or ready-to-use delivery.
• A new buffer system creates development and regulatory work without clear commercial benefit.
• The main barriers are sterile manufacturing, particulate control, container compatibility, and supply reliability.
• Patent-based exclusion appears less important than regulatory execution and hospital procurement access.
• A prefilled syringe, low-waste unit dose, or dependable generic supply model offers the clearest commercial opportunity.
• Compounded carbachol is a potential competitor during shortages, but an approved product can compete through standardized quality and workflow simplicity.

FAQs About MIOSTAT Excipient and Commercial Strategy

Is MIOSTAT preservative-free?

Yes. MIOSTAT is supplied as a single-use intraocular product, so a multidose preservative system is not required.

Can benzalkonium chloride be used in a carbachol intraocular product?

It would be an unattractive choice because the product is injected into the eye. A preservative-free design is more consistent with the route of administration and ocular-tolerability requirements.

Could MIOSTAT be reformulated as a prefilled syringe?

Yes, but the syringe would require separate evaluation of sterility, dose accuracy, container-closure integrity, particulate matter, extractables, leachables, and device compatibility.

Is carbachol still commercially attractive despite its age?

Yes, if the product solves supply, preparation, or waste problems. The commercial opportunity is operational rather than based on new pharmacology.

What is the main risk for a generic MIOSTAT developer?

The main risk is failure to achieve reliable sterile manufacturing and regulatory equivalence. Formulation complexity is less valuable than consistent quality, validated packaging, and uninterrupted supply.

References

1. U.S. Food and Drug Administration. (n.d.). MIOSTAT- carbachol injection, solution. FDA prescribing information.

2. DailyMed. (n.d.). MIOSTAT- carbachol intraocular solution. National Library of Medicine.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.